UK mineral medicines company Shield Therapeutics has appointed Dr Julian Howell as group medical director and VP of drug development.
He joins the specialty pharma company after spending six years at ProStrakan, where he led its clinical development and drug safety group.
Dr Howell spent six years in the NHS, gaining medical and surgical qualifications, and began his industry career with SmithKline Beecham and then at Roche, before moving to smaller companies.
Dr Howell said: “I am very pleased to be joining the team at Shield … I look forward to adding my clinical development experience and medical knowledge to the skilled team already in place to help ensure that our products become available as quickly and safely as possible to patients with such clear unmet medical needs.”
Shield Therapeutics has also appointed Dr Lynn Drummond to its board as a non-executive director.
She has over 25 years of management and advisory experience, spending 16 years at Rothschild in London, most recently as a managing director within the investment banking division, with a particular focus on transactions within the healthcare sector.